Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

By R. Andrade, M. Lucena, M. C. Fernández, G. Pelaez, K. Pachkoria, Elena García-Ruiz, B. García-Muñoz, R. González‐Grande, Á. Pizarro, J. A. Duran and 10 more. Gastroenterology, 2005

984 citations recorded by the source corpus.

Subfields: Emergency Medicine, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/62725535b5230e06ed919c34498b3accef5f592b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Mack
2. T. Karlsen
3. U. Beuers
4. D. Adams
5. G. Kullak-Ublick
6. E. Bjornsson
7. D. Assis
8. M. Mayo

Citations in the corpus

• EASL Clinical Practice Guidelines: Drug-induced liver injury. (2019, methodology): “Data corresponding to large prospective studies from the Spanish DILI registry and the US DILIN have also been published but are not population-based.(14,16,48)”
• ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. (2021, background): “Women account for 56%–70% in large studies of DILI, suggesting women are a greater risk of idiosyncratic DILI and possibly an increased risk of more severe injury (15,16,70).”
• EASL Clinical Practice Guidelines: management of cholestatic liver diseases. (2009, background): “Drug-induced cholestatic injury has a better prognosis than hepatocellular injury [179].”
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “(187,231,238,239) In accordance with “Hy’s law,” serum aminotransferase levels >3-fold ULN and total serum bilirubin level >2-fold ULN increase the risk of death or need for LT in 9%-12% of patients.(240-242) Satisfaction of criteria for Hy’s law supports the institution of glucocorticoid therapy.”